Japan-based Daiichi Sankyo (TYO: 4568) has reported revenues of JPY 1.37 trillion ($8.927 billion) for the first three quarters of the fiscal year 2024 (April 1, 2024, to March 31, 2025), representing a 16.6% year-on-year (YOY) growth. Core operating revenue stood at JPY 248.311 billion ($1.621 billion), up 27.6% YOY. Profit for the period was JPY 208.603 billion ($1.362 billion), up 27.1% YOY.
Growth Drivers: Antibody Conjugated Drugs (ADCs)
Antibody conjugated drugs (ADCs) were the main growth drivers for Daiichi Sankyo. The HER2-targeted ADC Enhertu (trastuzumab deruxtecan) generated JPY 404.4 billion ($2.638 billion) in sales during the first three quarters of FY2024 and is expected to record JPY 539.9 billion ($3.522 billion) for the entire fiscal year. Datroway (datopotamab deruxtecan-dlnk, Dato-Dxd), a Trop-2-directed antibody approved for HR+/HER2 breast cancer in Japan (December 2024) and the United States (January 2025), is expected to achieve sales of about JPY 400 million ($2.6 million) in FY2024.
Future Outlook
Daiichi Sankyo’s strong performance in the first three quarters of FY2024 underscores the company’s strategic focus on ADCs. With continued growth expected from Enhertu and the recent approval of Datroway, the company is well-positioned to maintain its upward trajectory in the global oncology market.-Fineline Info & Tech
